Neuphoria Therapeutics closed at $3.00 on Nov 3, down 1.32%, within 0.0% of its 52-week closing low. Volume of 2.4K shares was 0.08× its 20-day average (below normal).
Split-adjusted performance: -13.0% over one month, -44.4% over six months, -34.1% over one year.
Short interest was 6.4K shares at the Oct 15 settlement, down 67.9% from the prior report (0.1% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −26.0%, revenue growth +6.4%, net margin −38.1%, P/E 16.4×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| NEUPNeuphoria Therapeutics | $3.00 | −1.32% | −44.4% | — | — | — | $16.2M | |
| MTEXMannatech | $8.44 | +1.20% | +73.0% | +3.8% | 3.8% | — | $16.3M | Compare |
| MRKRMarker Therapeutics | $0.9581 | +6.33% | −36.5% | — | — | — | $16.0M | Compare |
| ALLRAllarity Therapeutics | $1.06 | +8.42% | −24.3% | — | — | — | $16.9M | Compare |
| PPCBPropanc Biopharma | $1.76 | +2.33% | −93.1% | — | — | — | $17.3M | Compare |
| CTXRCitius Pharmaceuticals | $0.5499 | −2.15% | −20.0% | — | −593.3% | — | $15.1M | Compare |
| KYNBKyntra Bio | $4.35 | −2.47% | −38.7% | — | — | — | $17.6M | Compare |
| BOLTBolt Biotherapeutics | $6.35 | +1.70% | +36.2% | −99.7% | −154400.0% | — | $15.0M | Compare |
| BIVIBioVie | $1.70 | +24.09% | +3.0% | — | — | — | $14.8M | Compare |
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company focused on therapies for serious central nervous system disorders. Its lead product candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor. The company has discontinued development of BNC210 for social anxiety disorder, while its BNC210 program for post-traumatic stress disorder is currently paused and no active clinical trial is underway. The company operates through a single operating and reporting segment focused on the discovery and development of allosteric ion-channel modulators for serious CNS disorders with high unmet medical need.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
